Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.50 |
| ▸ | TK1 | P04183 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 6/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HBB | P68871 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986800 | 0.87 | XDH (0.60) | XDHTK1PNPBLMUSP2 | |
| SCHEMBL1825531 | 0.86 | XDH (0.51) | XDHTK1PNPBLMUSP2 | |
| SCHEMBL15005119 | 0.85 | XDH (0.59) | XDHTK1PNPBLMUSP2 | |
| SCHEMBL26102379 | 0.77 | XDH (0.50) | XDHTK1PNPBLMUSP2 | |
| SCHEMBL72147 | 0.76 | XDH (0.50) | XDHTK1PNPBLMUSP2 | |
| SCHEMBL1831279 | 0.76 | XDH (0.50) | XDHTK1PNPBLMUSP2 | |
| SCHEMBL523465 | 0.76 | XDH (0.47) | XDHTK1PNPBLMUSP2 | |
| SCHEMBL2983847 | 0.74 | XDH (0.57) | XDHTK1PNPBLMUSP2 | |
| SCHEMBL10835122 | 0.74 | XDH (0.61) | XDHTK1PNPBLMUSP2 | |
| SCHEMBL79000 | 0.74 | XDH (0.51) | XDHTK1PNPBLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676768-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| US-9458158-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2016-10-04 | — | — | US | disclosed |
| US-9447098-B2 | Pteridines as FGFR inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9303029-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-05 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20160083377-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-24 | — | — | US | disclosed |
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20150291589-A1 | PTERIDINES AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| EP-1394163-A1 | Bicycloamide derivatives | Kuraray Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-0775705-B1 | Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein | KURARAY CO (JP) | 2004-02-11 | — | — | EP | disclosed |
| US-6482957-B2 | USEFUL AS AN INTERMEDIATE OF A CARBOCYCLIC NUCLEOSIDE ANTI-VIRAL AGENT; REACTING 2-AZABICYCLO(2.2.1)HEPT-5-EN-3-ONE WITH A SULFONYL HALIDE OR PHOSPHORYL HALIDE AND THEN WITH A NUCLEIC ACID BASE | KURARAY CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-6452004-B1 | USEFUL AS AN INTERMEDIATE OF A CARBOCYCLIC NUCLEOSIDE USEFULLY USED AS AN ANTI-VIRAL AGENT | KURARAY CO., LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20020115857-A1 | Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein | KURARAY CO., LTD. (JP) | 2002-08-22 | — | — | US | disclosed |
| US-6403568-B1 | FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) | YAMASA CORPORATION (JP) | 2002-06-11 | — | — | US | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6127539-A | Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein | KURARAY CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| US-5817812-A | Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein | KURARAY CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0775705-A2 | Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein | KURARAY CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291589-A1 | PTERIDINES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | XDH 3672/4885TK1 84/4885PNP 909/4885 |
| US-20150239883-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | XDH 695/4885TK1 646/4885PNP 274/4885 |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | XDH 502/4885TK1 356/4885PNP 902/4885 |
| US-20020115857-A1 | Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein | COASY, PPID, DHPS | XDH 1018/4885TK1 3652/4885PNP 1002/4885 |
| US-20160083377-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, CCNO | XDH 104/4885TK1 95/4885PNP 872/4885 |
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR3, ABL1 | XDH 1243/4885TK1 319/4885PNP 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.